Septerna (NASDAQ:SEPN – Get Free Report) is expected to be posting its quarterly earnings results before the market opens on Wednesday, February 19th. Analysts expect Septerna to post earnings of ($0.56) per share for the quarter.
Septerna Trading Up 12.2 %
Shares of Septerna stock opened at $12.96 on Tuesday. The company has a 50 day moving average price of $19.15. Septerna has a 52-week low of $10.34 and a 52-week high of $28.99.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently issued reports on the company. TD Cowen assumed coverage on Septerna in a research report on Tuesday, November 19th. They issued a “buy” rating on the stock. JPMorgan Chase & Co. started coverage on Septerna in a research report on Tuesday, November 19th. They set an “overweight” rating and a $38.00 price target on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $50.00 target price on shares of Septerna in a research note on Tuesday, February 11th. Finally, Wells Fargo & Company started coverage on Septerna in a research note on Tuesday, November 19th. They set an “overweight” rating and a $43.00 target price for the company.
About Septerna
We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.
Featured Articles
- Five stocks we like better than Septerna
- What Are Treasury Bonds?
- Airbnb’s Earnings: Sky High Results, Grounded Guidance?
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Kyndryl Soars on AI, Cybersecurity Growth—What’s Next?
- Investing in Construction Stocks
- Conflicting Signals: Tempus AI’s Stock Market Rally
Receive News & Ratings for Septerna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Septerna and related companies with MarketBeat.com's FREE daily email newsletter.